Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) Non Operating Income: 2020-2024

Historic Non Operating Income for SAB Biotherapeutics (SABS) over the last 5 years, with Dec 2024 value amounting to $8.8 million.

  • SAB Biotherapeutics' Non Operating Income rose 5954.91% to $58.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $61.9 million, marking a year-over-year increase of 897.60%. This contributed to the annual value of $8.8 million for FY2024, which is 313.80% up from last year.
  • SAB Biotherapeutics' Non Operating Income amounted to $8.8 million in FY2024, which was up 313.80% from -$4.1 million recorded in FY2023.
  • SAB Biotherapeutics' 5-year Non Operating Income high stood at $10.2 million for FY2022, and its period low was -$4.1 million during FY2023.
  • Moreover, its 3-year median value for Non Operating Income was $8.8 million (2024), whereas its average is $5.0 million.
  • In the last 5 years, SAB Biotherapeutics' Non Operating Income soared by 185,804.56% in 2022 and then slumped by 140.37% in 2023.
  • Yearly analysis of 5 years shows SAB Biotherapeutics' Non Operating Income stood at $3,996 in 2020, then spiked by 37.34% to $5,488 in 2021, then surged by 185,804.56% to $10.2 million in 2022, then crashed by 140.37% to -$4.1 million in 2023, then soared by 313.80% to $8.8 million in 2024.